Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply

Дата публикации: 01-07-2026 00:00:00

In Reply We welcome the opportunity to respond to the comments by Rhodes and Shoag regarding our recent article. The authors raise points that merit discussion, particularly those concerning unmeasured confounding, mortality ascertainment, and study design.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Reassessing Treatment Outcomes Following Immune-Related Adverse Events	0	10.29	01-07-2026
2	Caution in Interpreting Survival After for Salvage Focal Therapy vs Salvage Radical Prostatectomy—Reply	0	7.28	01-07-2026
3	Reticular Pseudodrusen and Cardiovascular Disease or Related Mortality in AREDS and AREDS2	0	8.07	01-07-2026
4	Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction—Reply	0	9.88	01-07-2026
5	Should Risk of Bias Be Assessed at the Outcome Level?	0	8.24	01-07-2026
6	Эксперт: показатели летальности от ковида могут быть связаны с недостатками лечения	0	0	13-08-2021
7	Opinion: What a recent op-ed got wrong about our Covid study	0	12	31-07-2026
8	A Dermatologist’s Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0	0	10.95	01-07-2026
9	STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment	0	12.74	30-07-2026
10	Comment on Author Simone O. Elias Bypasses Traditional Publishing with Open Access Release by Jeremy Impson	0	8.55	09-08-2026

Классификация: Мнения. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.34. Источник: jamanetwork.com.